From the Journals

Breast cancer care delayed when patients have high deductibles


 

FROM JOURNAL OF CLINICAL ONCOLOGY


Compared with controls, the hazard ratios (HR) for each parameter were as follows:

Time to first diagnostic breast imaging: HR = 0.96 (95% confidence interval 0.94-0.96)

Time to first breast biopsy: HR = 0.92 (0.89-0.95)

Time to early stage breast cancer diagnosis: HR = 0.83 (0.78-0.90)

Time to breast cancer chemotherapy: HR = 0.79 (0.72-0.86)

“The findings imply that the high out-of-pocket obligations under HDHPs [high-deductible health plans] might be a barrier to timely receipt of essential breast cancer services. Women in HDHPs might either delay presenting for concerning symptoms or, if proceeding along the pathway from breast cancer screening to diagnostic testing to treatment, be hesitant to undergo subsequent (and generally more expensive) care,” the authors wrote.

They noted that initially modest delays in diagnostic imaging appeared to snowball into longer delays as women proceeded through stages of care.

They recommend a strategy whereby insurers carve out exemptions to high deductibles for services such as diagnostic imaging and breast biopsy.

SOURCE: Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.

Pages

Recommended Reading

Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
MDedge Hematology and Oncology
AHA: Heart health helps optimize breast cancer outcomes
MDedge Hematology and Oncology
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
MDedge Hematology and Oncology
Cyclophosphamide extends PFS in elderly HER2+ breast cancer patients
MDedge Hematology and Oncology
Exercise during chemotherapy may yield long-term physical benefits
MDedge Hematology and Oncology
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
MDedge Hematology and Oncology
Measurement of physical activity and sedentary behavior in breast cancer survivors
MDedge Hematology and Oncology
Breast cancer deaths projected for 2018
MDedge Hematology and Oncology
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology